Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

DARK SECRETS: Jazz pharmaceuticals late stage multiple sclerosis study misses primary endpoint | Vintage Vibes

Jazz Pharmaceuticals (NASDAQ:JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with multiple sclerosis (MS).

The RELEASE MSS1 study evaluated the safety and efficacy of nabiximols oromucosal spray in 68 patients with multiple sclerosis (MS) spasticity, was the first and smallest, of the three clinical trials in the current program.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.